Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > Retatrutide for Sale > Tirzepatide Mazdutide Semax Ghk-Cu Mots-C Glutathione 99% Purity Peptide 20mg Vials Powder Raw Poeder Door to Door Delivery
Tirzepatide Mazdutide Semax Ghk-Cu Mots-C Glutathione 99% Purity Peptide 20mg Vials Powder Raw Poeder Door to Door Delivery buy - large image1
Tirzepatide Mazdutide Semax Ghk-Cu Mots-C Glutathione 99% Purity Peptide 20mg Vials Powder Raw Poeder Door to Door Delivery buy - image1
Tirzepatide Mazdutide Semax Ghk-Cu Mots-C Glutathione 99% Purity Peptide 20mg Vials Powder Raw Poeder Door to Door Delivery buy - image2
Tirzepatide Mazdutide Semax Ghk-Cu Mots-C Glutathione 99% Purity Peptide 20mg Vials Powder Raw Poeder Door to Door Delivery buy - image3
Tirzepatide Mazdutide Semax Ghk-Cu Mots-C Glutathione 99% Purity Peptide 20mg Vials Powder Raw Poeder Door to Door Delivery buy - image4
Tirzepatide Mazdutide Semax Ghk-Cu Mots-C Glutathione 99% Purity Peptide 20mg Vials Powder Raw Poeder Door to Door Delivery buy - image5
Tirzepatide Mazdutide Semax Ghk-Cu Mots-C Glutathione 99% Purity Peptide 20mg Vials Powder Raw Poeder Door to Door Delivery buy - image6

Tirzepatide Mazdutide Semax Ghk-Cu Mots-C Glutathione 99% Purity Peptide 20mg Vials Powder Raw Poeder Door to Door Delivery

TDS 7025 Inquiries

Unit Price:

$6/G FOB

Get Latest Price
CAS No.:

2381089-83-2

Grade:

Pharmaceutical Grade

Content:

99%

Port:

Gz

Brand:

YT

Packaging:

15mg/vial,10 vials/box

Price valid (until):

2028-12-31

Company Type:
Trader
Location:
China
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
Average Lead Time:
2 days
Qualification:
Main Products:

Retatrutide,Sermaglutide,Tirzepatide

  • Product Description

  • Seller Information

  • Inquiry History

  • Description

    Name:Lily

    Whatsapp:+86 19131996711

    Email Address:sales3ytpep@163.com


      Product Detail  


    What is Tirzepatide  ?

    Tirzepatide is a new dual-receptor channel agonist for glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP, also known as gastric inhibitory peptide). Administer once a week. Both GLP-1 and GIP are incretins, polypeptides secreted by the human gastrointestinal mucosa. The former can bind to receptors on pancreatic islet cells and stimulate insulin secretion, thus producing a hypoglycemic effect and delaying gastric excretion. Empty and suppress appetite, thereby controlling weight; while the latter has the functions of inhibiting gastric acid and pepsin secretion, stimulating insulin release, inhibiting gastric motility and emptying, and can supplement the GLP-1 receptor agonist effect. Tirzepatide combines two insulinotropic effects into a single molecule and represents a new class of drugs for the treatment of type 2 diabetes.

    Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control and weight loss than do Dulaglutide.

    Tirzepatide, also known as LY 3298176, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behavior has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies reported that tirzepatide mimics the actions of natural GIP at the GIP receptor. Tirzepatide was approved for improving blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.


    Function

    1.Weight loss 
    2. Anti-diabetes
    • Helps slow food leaving your stomach
    • Helps prevent your liver from making too much sugar
    • Helps the pancreas produce more insul when your blood sugar levels are high
    • Can help control blood glucose
    • Can reduce hyperglycemia, especially after meals
    • Can reduce fasting insul and fasting glucose
    • Can reduce hemoglobin A1c
    • Can decrease appetite and caloric intake, while inhibiting weight gain
    • Has been shown to lower triglyceride levels and oxidative stress from high LDL
    • Has been shown to help induce weight loss in obese patients with higher dosing
    • Helps decrease leptin and increase leptin sensitivity
    • Can increase the conversion of white fat to brown fat
    Application

    Tirzepatide has a similar sequence to semaglutide. The lys side chain in the sequence is modified with PEG, which is a functional group of phospholipids and can ine (GIP) and glucagon-like peptide-1 (GLP-1) in diabetes. It is being developed for the treatment of type 2 diabetes and has entered the clinical stage.
    Items Specifications
    Name Tirzepatide
    CAS Number 2023788-19-2
    Apperance Powder

    Shop High Purity QSC Ly3437943 Research Peptide 5mg 10mg  GLP-1R Peptide Retatrutide.OUDA-Detailed Image 1 Shop High Purity QSC Ly3437943 Research Peptide 5mg 10mg  GLP-1R Peptide Retatrutide.OUDA-Detailed Image 2 Shop High Purity QSC Ly3437943 Research Peptide 5mg 10mg  GLP-1R Peptide Retatrutide.OUDA-Detailed Image 3 Shop High Purity QSC Ly3437943 Research Peptide 5mg 10mg  GLP-1R Peptide Retatrutide.OUDA-Detailed Image 4


    logistics 


    Customers can specify express delivery, such as:  UPS/DHL/FedEX , etc. (Default express delivery: our cooperative logistics company)

    Shop High Purity QSC Ly3437943 Research Peptide 5mg 10mg  GLP-1R Peptide Retatrutide.OUDA-Detailed Image 5


    Company Profile  


    Yingpeptides Technology Co., Ltd focuses on the research and development and production of high potency polypeptide products, targeting the global market, and provides polypeptide API/raw material and preparation products. It has built polypeptide API workshops, bio-fermentation workshops, polypeptide purification and lyophilization workshops, and multifunctional injection workshops that meet the GMP requirements of mainstream markets such as the U.S. FDA, EU EMA, Japanese PMDA, and China NMPA. With the strong support of New Hope Group, the company has introduced advanced large-scale CS-PREP® industrial preparative liquid chromatography systems, becoming one of the few polypeptide companies in the industry with a capacity of tons.

    Shop High Purity QSC Ly3437943 Research Peptide 5mg 10mg  GLP-1R Peptide Retatrutide.OUDA-Detailed Image 6 Shop High Purity QSC Ly3437943 Research Peptide 5mg 10mg  GLP-1R Peptide Retatrutide.OUDA-Detailed Image 7 Shop High Purity QSC Ly3437943 Research Peptide 5mg 10mg  GLP-1R Peptide Retatrutide.OUDA-Detailed Image 8 Shop High Purity QSC Ly3437943 Research Peptide 5mg 10mg  GLP-1R Peptide Retatrutide.OUDA-Detailed Image 9


    Why choose us?


    Our Advantages.

    1.High quality with competitive price.

    2. All purity>99%.

    3. We are manufacturer and can provide high quality products with factory price.

    Shop Wholesale price Factory price top quality sample TirzepatideCAS 2023788-19-2 5mg-Detailed Image 10


     How to order from us


    Shop High Purity QSC Ly3437943 Research Peptide 5mg 10mg  GLP-1R Peptide Retatrutide.OUDA-Detailed Image 11

    ECHEMI Editorial Reference
    Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
    Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.

    Certificates
    • Tirzepatide Mazdutide Semax Ghk-Cu Mots-C Glutathione 99% Purity Peptide 20mg Vials Powder Raw Poeder Door to Door Delivery Certificates 1 TDS

    Basic Info
    Product Name:

    Retatrutide

    Other Name:

    Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide

    CAS No.:

    2381089-83-2

    InChIKeys:

    MLOLQJNKXBNWFW-SAGGEDDASA-N

    Molecular Weight:

    0

    EC Number:

    200-001-8

    Color/Form:

    White lyophilized

    Characteristics
    Water Solubility:

    Soluble in water (5mg/ml).

    Storage Conditions:

    -20°C

    Critical Temperature & Pressure:

    -20°C

    Research
    Class:

    Triple agonist — GCGR, GIPR, GLP-1R

    Status:

    Investigational (Phase 3)

    Mechanism:

    Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

    EC50 (Human GCGR):

    5.79 nM

    EC50 (Mouse GIPR):

    0.191 nM

    EC50 (Mouse GLP1R):

    0.794 nM

    EC50 (Mouse GCGR):

    2.32 nM

    EC50 (Human GLP1R):

    0.775 nM

    EC50 (Human GIPR):

    0.0643 nM

    Source:

    Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

    Clinical Development:

    NCT04881760; NCT05882045; NCT06354660

    References
    ChEMBL:

    CHEMBL5095485

    DrugBank:

    DB18993

    KEGG DRUG:

    D12430

    PubChem:

    PubChem

    Disclaimer:

    Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Retatrutide,Sermaglutide,Tirzepatide

    Location:

    No. 126 Dongtai Road, Pudong New Area, Shanghai

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    2 days

    Total Annual Revenue:

    $2.5 million-$5 million

    Total Employees:

    11-50

    Year of Establishment:

    2025

         
          Yingpeptides Technology Co., Ltd focuses on the research and development and production of high potency polypeptide products, targeting the global market, and provides polypeptide API/raw material and preparation products. It has built polypeptide API workshops, bio-fermentation workshops, polypeptide purification and lyophilization workshops, and multifunctional injection workshops that meet the GMP requirements of mainstream markets such as the U.S. FDA, EU EMA, Japanese PMDA, and China NMPA. With the strong support of New Hope Group, the company has introduced advanced large-scale CS-PREP® industrial preparative liquid chromatography systems, becoming one of the few polypeptide companies in the industry with a capacity of tons.


  • Inquiry History
    7025 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    Retatrutide 2381089-83-2

    3 MT Mar 28, 2026
    United Kingdom

    Retatrutide - 2381089-83-2

    1 G Feb 10, 2026
    United States

    Retatrutide CAS 2381089-83-2 10mg vial

    20 MT Mar 7, 2026
    United States

    Factory Retatrutide API 99% Purity CAS 2381089-83-2

    5 KG Nov 10, 2025
    United Kingdom

    Peptide powder Retatrutide 99% pure for Body building cas 2381089-83-2 Weight Loss Peptide with COA

    1 MT Mar 22, 2026
    United States

    2381089-83-2

    100 G Jul 14, 2026
    United States

    2381089-83-2

    100 G Feb 24, 2026
    United States

    2381089-83-2

    100 MT Dec 9, 2023
    United States

    Retatrutide 2381089-83-2

    200 MG May 16, 2026
    United Kingdom

    2381089-83-2 retatrutide

    300 MG Feb 13, 2026
    United States

    Retatrutide 2381089-83-2 wholesale

    500 MT Nov 3, 2023
    United States

    Retatrutide CAS 2381089-83-2 99%

    10 PCS Feb 21, 2026
    Poland

    CAS 2381089-83-2 (Custom Peptide)

    40 MT Apr 10, 2026
    Austria

    Peptide Retatruide CAS 2381089-83-2

    100 MT Apr 4, 2026
    Austria

    Retatrutide CAS 2381089-83-2 10mg vial

    20 PCS Feb 10, 2026
    United States

    GLP-1 / GIP Retatrutide cas 2381089-83-2

    1 MT Oct 16, 2024
    United States

    Retatrutide 99% High Quality CAS 2381089-83-2

    1 G Jan 23, 2026
    United States

    Injection Peptide Tirzepatide/Retatrutide/ Semaglutide Peptides CAS 2381089-83-2

    10  Oct 21, 2023
    Australia

    GMP Grade 99% Retatrutide Lyophilized Powder CAS 2381089-83-2

    10 G Jun 12, 2026
    Palestine

    Factory 99% Purity Retatrutide Peptide CAS 2381089-83-2 Door-To-Door Service

    10 MG Mar 16, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.